Risk factor
Negligible price volatility
Profitability factor
Favourable analyst view
About
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB
Target Price
The average target price of FAGR.BR is 28.5 and suggests 33.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i